Replies to post #798387 on NorthWest Biotherapeutics Inc (NWBO)

[Kam8]

Hi Sir, Great posts from stock twist

Tompopcorn89

$NWBO 🔥 Could they have released the PRE-14A because approval hit today?

Yes — that scenario is very plausible.
Not guaranteed, but totally in the realm of how biotech timing works.

Here’s why:
✅ 1. Companies often release “administrative” filings right before MAJOR news

This is a real pattern.

Before:
• approvals
• partnerships
• buyouts
• financings
• uplist applications

Companies clean up their corporate governance in advance so the big news can land cleanly.

A PRE-14A is essentially house-cleaning.

And 900 million new authorized shares isn’t housekeeping — it’s installing extra bedrooms because you expect visitors.

[Kam8]

Great post from stocktwits .....Tompopcorn89

😍$NWBO 😍
NWBO Q2 ? Q3 Comparison: The REAL Takeaways (They’ve Dotted Every “i” & Crossed Every “t”)

Here’s what actually changed from Q2 to Q3 — and why it matters:

1. MAA Process Is Effectively DONE

Q2 was “we’re working on it.”
Q3 is “the process is finished and we’ll announce results when regulators are done.”
That’s the closest you’ll ever get to “approval is imminent” without saying it outright.

2. Advent Acquisition Finalized

Q2 = negotiating.
Q3 = definitive agreement signed, closing conditions met.
You don’t buy your contract manufacturer right before approval unless you expect to become a commercial company.
Huge tell.

3. UK Manufacturing (Sawston) Is in Full Commercial Prep
• Engineering finalized
• Procurement accelerated
• Major equipment acquired
• Avoided 10–12 month lead times
This is commercial scaling, not R&D.
Bullish
Nov 15, 2025 7:49 AM

[Kam8]

Great post from stocktwits:::::::::
😍4. US Manufacturing: The BIG One🥰

Q2 = down to two finalists.
Q3 = site selected, responsibilities assigned, and hiring has begun.
You do NOT start building and staffing a US manufacturing footprint if you think the UK approval is still questionable.
This is “global rollout mode,” not “wait and see.”

5. Compassionate Use Expansion

They’re now pursuing multiple hospital arrangements and expanded access programs.
Hospitals don’t sign on unless they believe commercial approval is near.

6. DCVax-Direct Just Leveled Up

Q3 shows:
• New clinical trial designs
• Additional agents
• Multiple routes of administration
• Pre-conditioning regimens
This is a pipeline being built behind DCVax-L — not a one-drug company.

7. Overall Tone Shift = They’re Preparing for Market, Not Hoping for it

Everything in Q3 reads like:
• Infrastructure build-out
• Staffing
• Expansion
• Scaling
• Commercial readiness
Not theoretical. Not speculative. Not delayed.
Nov 15, 2025 7:50 AM